文献速递瓣膜病与结构性心脏病血脂与心血管预防

脑栓塞保护装置与经导管主动脉瓣置换术结局:TVT注册研究结果

Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve Therapy Registry.
PubMed 文献 · Circulation · 2021-02-23

主要工具变量分析未发现EPD使用与院内卒中相关(校正相对风险0.90,95%CI 0.68-1.13),次要倾向评分加权分析显示EPD使用与院内卒中风险降低18%相关(校正比值比0.82,95%CI 0.69-0.97)。

要点

  • 工具变量分析未发现EPD使用与院内卒中显著相关(校正相对风险0.90,95%CI 0.68-1.13)。
  • 倾向评分加权分析显示EPD使用与院内卒中风险降低18%相关(校正比值比0.82,95%CI 0.69-0.97)。
  • EPD使用率至2019年12月达13%的TAVR手术和28%的中心,各医院间差异大。

核心结论

  • 主要工具变量分析未发现EPD使用与TAVR后院内卒中相关,次要倾向评分加权分析仅显示院内卒中风险轻度降低。

主要发现

  • EPD使用率随时间增加,至2019年12月达到28%的中心和13%的TAVR手术。
  • 各医院EPD使用差异大,2019年最后季度8%的中心EPD使用率超过50%,72%的中心未使用EPD。
  • 主要工具变量分析:EPD使用与院内卒中无关联(校正相对风险0.90,95%CI 0.68-1.13;绝对风险差-0.15%,95%CI -0.49至0.20)。
  • 次要倾向评分加权分析:EPD使用与院内卒中风险降低18%相关(校正比值比0.82,95%CI 0.69-0.97;绝对风险差-0.28%,95%CI -0.52至-0.03)。
  • 次要终点和亚组分析结果总体一致。

临床怎么用

  • 当前证据不足以常规推荐TAVR中使用EPD预防院内卒中,需个体化评估。
  • 研究结果支持开展大规模随机对照试验验证EPD的临床获益。

局限性

  • 观察性研究设计,存在残余混杂可能,工具变量分析依赖排他性假设。
  • 次要倾向评分分析结果与主要分析不一致,需谨慎解读。
  • 仅评估院内卒中结局,缺乏长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stroke remains a devastating complication of transcatheter aortic valve replacement (TAVR), which has persisted despite refinements in technique and increased operator experience. While cerebral embolic protection devices (EPDs) have been developed to mitigate this risk, data regarding their impact on stroke and other outcomes after TAVR are limited. METHODS: We performed an observational study using data from the Society for Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Patients were included if they underwent elective or urgent transfemoral TAVR between January 2018 and December 2019. The primary outcome was in-hospital stroke. To adjust for confounding, the association between EPD use and clinical outcomes was evaluated using instrumental variable analysis, a technique designed to support causal inference from observational data, with site-level preference for EPD use within the same quarter of the procedure as the instrument. We also performed a propensity score-based secondary analysis using overlap weights. RESULTS: Our analytic sample included 123 186 patients from 599 sites. The use of EPD during TAVR increased over time, reaching 28% of sites and 13% of TAVR procedures by December 2019. There was wide variation in EPD use across hospitals, with 8% of sites performing >50% of TAVR procedures with an EPD and 72% performing no procedures with an EPD in the last quarter of 2019. In our primary analysis using the instrumental variable model, there was no association between EPD use and in-hospital stroke (adjusted relative risk, 0.90 [95% CI, 0.68-1.13]; absolute risk difference, -0.15% [95% CI, -0.49 to 0.20]). However, in our secondary analysis using the propensity score-based model, EPD use was associated with 18% lower odds of in-hospital stroke (adjusted odds ratio, 0.82 [95% CI, 0.69-0.97]; absolute risk difference, -0.28% [95% CI, -0.52 to -0.03]). Results were generally consistent across the secondary end points, as well as subgroup analyses. CONCLUSIONS: In this nationally representative observational study, we did not find an association between EPD use for TAVR and in-hospital stroke in our primary instrumental variable analysis, and found only a modestly lower risk of in-hospital stroke in our secondary propensity-weighted analysis. These findings provide a strong basis for large-scale randomized, controlled trials to test whether EPDs provide meaningful clinical benefit for patients undergoing TAVR.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Butala NM, Makkar R, Secemsky EA, et al. Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve Therapy Registry. Circulation. 2021. PMID: 33619968. doi:10.1161/CIRCULATIONAHA.120.052874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。